1. Acute leukemia transformed from myeloproliferative neoplasms with Philadelphia chromosome-negative: report of eight cases and review of literature
Yuanfei MAO ; Qiusheng CHEN ; Yu CHEN ; Junmin LI ; Wen WU
Journal of Leukemia & Lymphoma 2018;27(8):474-478
Objective:
To analyze the disease progression of acute leukemia (AL) transformed from myeloproliferative neoplasms (MPN) with Philadelphia chromosome-negative (Ph-), and to investigate its mechanism and clinical treatments.
Methods:
The pre-transformation and post-transformation data of 8 AL patients with Ph- MPN from July 2013 to December 2017 in Ruijin Hospital Affiliated of Shanghai Jiao Tong University School of Medicine were retrospectively analyzed. The literature was also reviewed.
Results:
All 8 cases transformed into acute myelogenous leukemia (AML). The median conversion time was 47.5 months (2-180 months), and the median survival time after transformation was 2 months (1-17 months). Three of 4 patients who undergone AML-related molecular biology after transformation had new mutant genes. One refractory patient achieved stable disease after oral treatment with ruxolitinib.
Conclusions
AML patients transformed from MPN have poor clinical outcomes and short survival time. Allogeneic hematopoietic stem cell transplantation is the only known potential curative treatment strategy and JAK2 inhibitor may be effective.
2.A phase IV study of homoharringtonine, cytarabine, aclacinomycin and G-CSF (HCAG) regimen compared with traditional IA regimen in the treatment of newly diagnosed elderly acute myeloid leukemia patients
Zhao LIU ; Yunxiang ZHANG ; Lining WANG ; Zheng XIA ; Yuanfei MAO ; Huijin ZHAO ; Jianhua YOU ; Yang YU ; Yubing ZHAO ; Yuhong REN ; Ya LI ; Yan WANG ; Qiusheng CHEN ; Junmin LI ; Yu CHEN
Journal of Shanghai Jiaotong University(Medical Science) 2017;37(8):1100-1105
Objective · To compare the efficacy and prognostic factors of HCAG regimen with traditional IA regimen in the treatment of newly diagnosed elderly acute myeloid leukemia (AML) patients. Methods · Forty-one patients with AML (aged 55-71 years) were randomly divided into two groups (Group HCAG and Group IA) between 2014 and 2016 for induction and consolidation therapy. Multivariate analysis was applied to identify prognostic factors for relapse-free survival (RFS). Results · A total of 29 patients (70.7%) achieved complete remission (CR). The estimated 2-year overall survival (OS) was 66.8% in Group HCAG and 75.4% in Group IA (P=0.913). The estimated 2-year RFS was 61.8% in Group HCAG and 49.1% in Group IA (P=0.411). Age remained as the unfavorable prognostic factor, leading to significant differences in OS and RFS. In addition, RFS was influenced by cytogenetic/molecular risk stratification. Conclusion · Although HCAG seemed not to particularly benefit the group, the dose reduction of anthracyclines may be applied in elderly patients with comparable short-time outcome. Furthermore, the introduction of homoharringtonine resulted in an improvement of treatment response for more than 20% compared with CAG regimen.
3. A multicenter, retrospective study of pathogenic bacteria distribution and drug resistance in febrile neutropenic patients with hematological diseases in Shanghai
Jun ZHU ; Jiong HU ; Yuanfei MAO ; Fangyuan CHEN ; Jianyi ZHU ; Jumei SHI ; Dandan YU ; Siguo HAO ; Rong TAO ; Peng LIU ; Shiyang GU ; Jian HOU ; Haiyan HE ; Aibin LIANG ; Yi DING ; Ligen LIU ; Yinghua XIE ; Qi ZHU ; Yehua YU ; Yonghua YAO ; Wei CHEN ; Huili XU ; Xiuhua HAN ; Chun WANG
Chinese Journal of Hematology 2017;38(11):945-950
Objective:
To investigate the pathogen spectrum distribution and drug resistance of febrile neutropenic patients with hematological diseases in Shanghai.
Methods:
A retrospective study was conducted on the clinical isolates from the febrile neutropenic patients hospitalized in the departments of hematology in 12 general hospitals in Shanghai from January 2012 to December 2014. The drug susceptibility test was carried out by Kirby-Bauer method. WHONET 5.6 software was used to analyze pathogenic bacteria and drug susceptibility data.
Results:
A total of 1 260 clinical isolates were collected from the febrile neutropenic patients. Gram-positive bacteria accounted for 33.3% and Gram-negative bacteria accounted for 66.7%.